Evidence for Cyclophosphamide-Induced Transitional Cell Carcinoma in a Renal Transplant Patient
Authors:
- 1 November 1988
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 140 (5 Part 1) , 1009-1011
Abstract
Cyclophosphamide treatment has been associated with bladder cancer in a number of case reports but no causal relationship has been proved since nearly all of these patients were treated with the drug for malignant disease. We describe a patient who received cyclophosphamide after cadaveric renal transplantation to prevent rejection. Transitional cell carcinoma developed in the native bladder and in the donor transplanted ureter (20-year-old donor) 13 years later despite no identifiable risk factors. This case strengthens the argument that cyclophosphamide has a carcinogenic potential on the urinary tract epithelium.Keywords
This publication has 16 references indexed in Scilit:
- Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritisArthritis & Rheumatism, 1983
- Bladder malignancy in patient receiving cyclophosphamide for benign diseaseUrology, 1981
- Urothelial susceptibility to tumor cell implantation influence of cauterizationCancer, 1980
- Late hemorrhagic cystitis following low-dose cyclophosphamide therapyUrology, 1979
- The Incidence Of Bladder Cancer after Cyclophosphamide TherapyJournal of Urology, 1979
- Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid ArthritisAnnals of Internal Medicine, 1979
- Cyclophosphamide and the bladder.BMJ, 1971
- Urinary-Bladder Fibrosis and Telangiectasia Associated with Long-Term Cyclophosphamide TherapyNew England Journal of Medicine, 1971
- Metabolism of cyclophosphamideCancer, 1967
- Cytological study of the effect of cyclophosphamide on the epithelium of the urinary bladder in manCancer, 1964